Neurofibromatosis

Active Research Protocols

  1. 00-CH-0093 – Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma
  2. 01-C-0027 – Natural History of Plexiform in Neurofibromatosis Type I
  3. 04-C-0080 – Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
  4. 05-HG-0152 – Variation in Gene Expression in Neurofibromatosis Type 1
  5. 06-C-0043 – Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors
  6. 06-HG-0134 – Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1
  7. 08-C-0079 – Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
  8. 08-C-0096 – A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
  9. 08-C-0130 – A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
  10. 08-N-0044 – A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2)
  11. 09-M-0022 – The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory, Pilot Study
  12. 10-N-0193 – Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients
  13. 11-C-0115 – Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma
  14. 11-C-0161 – A Phase 1 Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate (Selumetinib Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
  15. 12-C-0058 – A Phase II Study of Everolimus (RAD001) for Children with Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas
  16. 12-C-0136 – A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
  17. 12-C-0148 – SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
  18. 12-C-0155 – Acceptance and Commitment Therapy for Adolescents and Adults with Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
  19. 12-C-0160 – Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults with Chronic Illness and their Parents
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014